LL-37

LL-37 is an endogenous antimicrobial peptide studied in innate immunity, membrane disruption, chemotaxis, biofilm biology, inflammation, wound models, and host-defense signaling.

Can interact with microbial membranes and multiple host receptors and nucleic acids, producing context-dependent antimicrobial and immunomodulatory effects.

Predominantly preclinical with limited translational research.

Level IV, Predominantly preclinical

Effects are highly concentration-, environment-, and cell-type-dependent. Pro-inflammatory and cytotoxic activity can occur alongside antimicrobial effects.

Potential concerns include cytotoxicity, hemolysis, inflammatory activation, immunogenicity, and poorly characterized systemic effects.

No FDA-approved LL-37 drug product; FDA has identified safety-information gaps for compounded LL-37.

Supplied strictly for in-vitro and ex-vivo laboratory research. Not for human or veterinary administration, diagnostic, or therapeutic use. Import and regulatory compliance remain the responsibility of the receiving researcher.

• LL-37, 5 mgLyophilized

Every Cendrix lot ships with an HPLC purity chromatogram, mass-spectrometry identity confirmation, appearance and reconstitution observations, and endotoxin testing where applicable. Lot certificates are retrievable from the Quality page using the lot number printed on the vial.

External searches link to PubMed, ClinicalTrials.gov, Google Scholar, and FDA records. Cendrix does not endorse interpretations published in third-party sources.